Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 8/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 6/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617571 | 1.00 | CYP2D6 (0.41) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL1617597 | 0.77 | CYP2D6 (0.43) | CYP2D6DHFR | |
| SCHEMBL9607815 | 0.73 | CSNK1A1 (0.43) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL1617136 | 0.68 | DHFR (0.33) | CYP2D6DHFR | |
| SCHEMBL1617661 | 0.66 | MBOAT4 (0.30) | CYP2D6 | |
| SCHEMBL463895 | 0.66 | MAOB (0.56) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL8845464 | 0.65 | MAOB (0.65) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL10540521 | 0.65 | MAOB (0.65) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL2261976 | 0.65 | MAOB (0.65) | CYP2D6HTR2CMAOBHTR2BHTR2A | |
| SCHEMBL605028 | 0.64 | HRH4 (0.48) | HTR2CMAOBHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | claimed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-8716475-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | disclosed |
| US-8415366-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-09 | — | — | US | disclosed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | disclosed |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | CYP2D6 1457/4885HTR2C 87/4885MAOB 2945/4885 |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | CYP2D6 1457/4885HTR2C 87/4885MAOB 2945/4885 |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | CYP2D6 1225/4885HTR2C 115/4885MAOB 3246/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | CYP2D6 2655/4885HTR2C 199/4885MAOB 3336/4885 |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | CYP2D6 1457/4885HTR2C 87/4885MAOB 2945/4885 |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | CYP2D6 1457/4885HTR2C 87/4885MAOB 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.